Literature DB >> 27214073

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

P Montesinos1, M Cabrero2, D Valcárcel3, M Rovira4, J A García-Marco5, J Loscertales6, C Moreno7, R Duarte8, M J Terol9, N Villamor10, P Abrisqueta3, D Caballero2, J Sanz1, J Delgado4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27214073     DOI： 10.1038/bmt.2016.145

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

Authors:  P Dreger; P Corradini; E Kimby; M Michallet; D Milligan; J Schetelig; W Wiktor-Jedrzejczak; D Niederwieser; M Hallek; E Montserrat
Journal:  Leukemia       Date:  2006-11-16       Impact factor: 11.528

2.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

Authors:  Stephan Stilgenbauer; Andrea Schnaiter; Peter Paschka; Thorsten Zenz; Marianna Rossi; Konstanze Döhner; Andreas Bühler; Sebastian Böttcher; Matthias Ritgen; Michael Kneba; Dirk Winkler; Eugen Tausch; Patrick Hoth; Jennifer Edelmann; Daniel Mertens; Lars Bullinger; Manuela Bergmann; Sabrina Kless; Silja Mack; Ulrich Jäger; Nancy Patten; Lin Wu; Michael K Wenger; Günter Fingerle-Rowson; Peter Lichter; Mario Cazzola; Clemens M Wendtner; Anna M Fink; Kirsten Fischer; Raymonde Busch; Michael Hallek; Hartmut Döhner
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

3.  Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

Authors:  A C Rawstron; S Böttcher; R Letestu; N Villamor; C Fazi; H Kartsios; R M de Tute; J Shingles; M Ritgen; C Moreno; K Lin; A R Pettitt; M Kneba; E Montserrat; F Cymbalista; M Hallek; P Hillmen; P Ghia
Journal:  Leukemia       Date:  2012-07-31       Impact factor: 11.528

4.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

5.  Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.

Authors:  M Hahn; S Böttcher; S Dietrich; U Hegenbart; M Rieger; P Stadtherr; A Bondong; R Schulz; M Ritgen; T Schmitt; T H Tran; M Görner; I Herth; T Luft; S Schönland; M Witzens-Harig; T Zenz; M Kneba; A D Ho; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

Review 6.  Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

Authors:  Ron Ram; Rainer Storb
Journal:  Leuk Lymphoma       Date:  2013-01-24

7.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

8.  Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Authors:  Andrew W Pawluczkowycz; Frank J Beurskens; Paul V Beum; Margaret A Lindorfer; Jan G J van de Winkel; Paul W H I Parren; Ronald P Taylor
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

9.  Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.

Authors:  Mauricette Michallet; Gerard Socié; Mohamad Mohty; Mohamad Sobh; Jacques-O Bay; Stéphane Morisset; Hélène Labussière-Wallet; Reza Tabrizi; Noel Milpied; Pierre Bordigoni; Jean El-Cheikh; Didier Blaise
Journal:  Exp Hematol       Date:  2012-10-23       Impact factor: 3.084

10.  Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

Authors:  J R Brown; H T Kim; P Armand; C Cutler; D C Fisher; V Ho; J Koreth; J Ritz; C Wu; J H Antin; R J Soiffer; J G Gribben; E P Alyea
Journal:  Leukemia       Date:  2012-08-14       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.